<DOC>
	<DOCNO>NCT01110356</DOCNO>
	<brief_summary>research study Ferric carboxymaltose treat fatigue/exhaustion symptom , believe due iron deficiency .</brief_summary>
	<brief_title>Ferric Carboxymaltose Treatment Improve Fatigue Symptoms Iron-deficient Non-anaemic Women Child Bearing Age</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Signed informed consent prior study specific procedure . Premenopausal , regularly menstruate woman . Age ≥18 year . Body weight 50 90 kg . Haemoglobin ≥115 g/L . Iron deficiency screen define follow : Sferritin level &lt; 50 ng/mL , AND , TfS &lt; 20 % , OR , Sferritin level &lt; 15 ng/mL . Serum Creactive protein : &lt; 5 mg/L oral contraception , OR , &lt; 20 mg/L use oral contraception . Minimum total score 5 Piper Fatigue Scale ( PFS ) ( mean item 2 23 ) . Negative pregnancy test ( serum human chorionic gonadotropin ( hCG ) screening . Normal level vitamin B12 folic acid screening . Adequate contraception study period 1 month follow study completion . Availability willingness complete study visit procedure per protocol . Haemoglobin level &lt; 115 g/L . Haemoglobinopathy . Haemochromatose . Major depressive disorder base Patient Health Questionnaire ( PHQ9 ) ( 5 item score ≥2 ; one correspond question number 1 2 ) . Any active unstable concurrent medical condition ( e.g. , cancer , renal dysfunction , liver dysfunction ( aspartate aminotransferase ( AST ) ; alanine aminotransferase ( ALT ) &gt; 3fold upper limit ) , angina ( Class IV ) . Known human immunodeficiency virus/acquired immunodeficiency syndrome , hepatitis B virus hepatitis C virus infection . Chronic inflammatory disease ( e.g. , rheumatoid arthritis ; inflammatory bowel disease ) . Documented history clinically significant level sleep apnoea define 5 episode per hour type apnoea . Intake concurrent medication could interfere physical mental performance ( e.g. , antidepressive , antihistamine , narcotic chemotherapeutic agent know cause drowsiness ) . Important recent weight loss ( &gt; 10 % within past month ) . Body weight &lt; 50 kg &gt; 90 kg . Thyroid dysfunction , thyroid stimulate hormone &gt; 4 μU/mL . Intake iron preparation 4 week prior screen . Use gestagens e.g. , Implanon , Mirena , DepoProvera menstruation repression ( see Section 7.7 , Prohibited Therapy Concomitant Treatment , page 35 ) . Known hypersensitivity FCM iron preparation . Pregnancy ( positive hCG test screening ) breast feeding . Participation interventional trial within 4 week prior screen . Inability fully comprehend and/or perform study procedure provide write consent Investigator 's opinion . Subject use adequate contraceptive precaution study 1 month last dose study medication . A highly effective method birth control define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence vasectomise partner . Subject previously enter study . Subject available followup assessment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>